GlassScriptPhysician profile
Michael Schmerler
NPI 1649380619
$7,971.07
in general payments reported to CMS, 2019-2025
47 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,642 · 2020: $379 · 2021: $2,046 · 2022: $659 · 2023: $976 · 2024: $246 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838 · Consulting Fee: $300 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.37 |
| Consulting Fee | $300.00 |
| Education | $107.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,786.34 | 2019-2025 | Tysabri, Vumerity, Tecfidera |
| Abbvie INC. | $1,057.14 | 2019-2025 | Ubrelvy, Qulipta |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Genzyme Corporation | $432.45 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $307.72 | 2023-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $292.03 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $262.12 | 2021 | |
| Greenwich Biosciences, INC. | $249.89 | 2019 | |
| Sunovion Pharmaceuticals INC. | $211.05 | 2019 | |
| Alexion Pharmaceuticals, INC. | $210.39 | 2019-2025 | Ultomiris |
| Ucb, INC. | $195.31 | 2019-2025 | Fintepla |
| Teva Pharmaceuticals USA, INC. | $185.67 | 2019-2021 | |
| Lilly USA, LLC | $158.91 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Amneal Pharmaceuticals LLC | $158.25 | 2019-2025 | Crexont |
| Novartis Pharmaceuticals Corporation | $146.71 | 2019-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schmerler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.